Reported results
- Research and development expense for the three months ended September 30, 2026, totaled $9.2 million.
- General and administrative expense for the three months ended September 30, 2026, totaled $3.9 million.
- Net cash used in operating activities for the three months ended September 30, 2026, totaled $12.6 million.
- The net loss for the three months ended September 30, 2026, was $13.9 million, or $0.12 per basic and diluted share.
- Cash, cash equivalents and short-term investments of approximately $202.1 million as of September 30, 2026.
Guidance
- Company operations expected to be funded through 2029.
- NDV-01 United States IND submission expected by year-end 2026.
- Sepranolone United States IND submission expected by year-end 2026.
Price and volatility reaction
The stock moved +1.2% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 4.16 | 2026-11-12 |
| Close after release | 4.21 | 2026-11-13 |
| Realised move | +1.2% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
